A Pilot Study of the Use of 2[ 18F]-fluoro-2-deoxy-D-glucose-Positron Emission Tomography to Assess the Distribution of Activated Lymphocytes in Patients With Systemic Lupus Erythematosus

Arthritis and Rheumatism

Volumn 50, Issue 4, 2004, Pages 1233-1238

  Nowak, Miroslawa ^a   Carrasquillo, Jorge A ^b   Yarboro, Cheryl H ^a   Bacharach, Steven L ^b   Whatley, Millie ^b   Valencia, Xavier ^a   Takada, Kazuki ^a   Brust, Douglas G ^c   Illei, Gabor G ^a,d  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FLUORODEOXYGLUCOSE F 18; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ADULT; ARTICLE; BODY MASS; CELL POPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; LYMPH NODE; LYMPHOCYTE ACTIVATION; LYMPHOID ORGAN; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; STANDARDIZATION; STATISTICAL SIGNIFICANCE; SYSTEMIC LUPUS ERYTHEMATOSUS; THYMUS;

ADULT; BIOLOGICAL MARKERS; FLUORODEOXYGLUCOSE F18; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTES; LYMPHOID TISSUE; MIDDLE AGED; PILOT PROJECTS; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 1842632405     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.20150     Document Type: Article

References (21)

1. Alcocer-Varela J, Alarcon-Riquelme M, Laffon A, Sanchez-Madrid F, Alarcon-Segovia D. Activation markers on peripheral blood T cells from patients with active or inactive systemic lupus erythematosus: correlation with proliferative responses and production of IL-2. J Autoimmun 1991;4:935-45.
2. Davis JC Jr, Austin H III, Boumpas D, Fleisher TA, Yarboro C, Larson A, et al. A pilot study of 2-chloro-2′-deoxyadenosine in the treatment of systemic lupus erythematosus-associated glomerulonephritis. Arthritis Rheum 1998;41:335-43.
3. Kubota R, Kubota K, Yamada S, Tada M, Ido T, Tamahashi N. Active and passive mechanisms of [fluorine-18] fluorodeoxyglucose uptake by proliferating and prenecrotic cancer cells in vivo: a microautoradiographic study. J Nucl Med 1994;35:1067-75.
4. Botti C, Negri DR, Seregni E, Ramakrishna V, Arienti F, Maffioli L, et al. Comparison of three different methods for radiolabelling human activated T lymphocytes. Eur J Nucl Med 1997;24:497-504.
5. Doherty MJ, Barrington SF, Campbell M, Lowe J, Bradbeer CS. PET scanning and the human immunodeficiency virus-positive patient. J Nucl Med 1997;38:1575-83.
6. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
7. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992;35:630-40.
8. Valencia X, Olson D, He L, Illei G, Lipsky P. CD4+CD25+ T regulatory cells in autoimmune diseases [abstract]. Arthritis Rheum 2003;48 Suppl 9:S194.
9. Rubin RL, Salomon DR, Guerrero RS. Thymus function in drug-induced lupus. Lupus 2001;10:795-801.
10. Nakahara T, Fujii H, Ide M, Nishiumi N, Takahashi W, Yasuda S, et al. FDG uptake in the morphologically normal thymus: comparison of FDG positron emission tomography and CT. Br J Radiol 2001;74:821-4.
11. Brink I, Reinhardt MJ, Hoegerle S, Altehoefer C, Moser E, Nitzsche EU. Increased metabolic activity in the thymus gland studied with 18F-FDG PET: age dependency and frequency after chemotherapy. J Nucl Med 2001;42:591-5.
12. Tanegashima A, Yamashita A, Yamamoto H, Fukunaga T. Human parathymic lymph node: morphological and functional significance. Immunology 1999;97:301-8.
13. Brekelmans P, van Soest P, Voerman J, Platenburg PP, Leenen PJ, van Ewijk W. Transferrin receptor expression as a marker of immature cycling thymocytes in the mouse. Cell Immunol 1994;159:331-9.
14. Brekelmans P, van Soest P, Leenen PJ, van Ewijk W. Inhibition of proliferation and differentiation during early T cell development by anti-transferrin receptor antibody. Eur J Immunol 1994;24:2896-902.
15. Hang L, Theofilopoulos AN, Balderas RS, Francis SJ, Dixon FJ. The effect of thymectomy on lupus-prone mice. J Immunol 1984;1809-13.
16. Mevorach D, Perrot S, Buchanan NM, Khamashta M, Laoussadi S, Hughes GR, et al. Appearance of systemic lupus erythematosus after thymectomy: four case reports and review of the literature. Lupus 1995;4:33-7.
17. Steven MM, Westedt ML, Eulderink F, Hazevoet HM, Dijkman JH, Cats A. Systemic lupus erythematosus and invasive thymoma: report of two cases. Ann Rheum Dis 1984;43:825-8.
18. Genty I, Jean R, Cretel E, Xeridat B, Astoul P, Poulain P, et al. Thymoma and disseminated lupus erythematosus: two new cases and review of the literature. Rev Med Interne 2001;22:475-84.
19. Zandman-Goddard G, Lorber M, Shoenfeld Y. Systemic lupus erythematosus and thymoma-a double-edged sword. Int Arch Allergy Immunol 1995;108:99-102.
20. Aarli JA, Gilhus NE, Matre R. Myasthenia gravis with thymoma is not associated with an increased incidence of non-muscle autoimmune disorders. Autoimmunity 1992;11:159-62.
21. Gerli R, Paganelli R, Cossarizza A, Muscat C, Piccolo G, Barbieri D, et al. Long-term immunologic effects of thymectomy in patients with myasthenia gravis. J Allergy Clin Immunol 1999;103:865-72.